Purpose: To summarize the top 10 most influential peer-reviewed infectious diseases (ID) pharmacotherapy articles published in the year 2018. Summary: Members of the Houston Infectious Diseases Network (HIDN) nominated articles that were thought to have most notably contributed to ID pharmacotherapy in 2018, including those related to human immunodeficiency virus (HIV). A total of 26 articles were nominated: 22 articles pertaining to general ID pharmacotherapy and 4 articles involving HIV/ AIDS. To select the most significant articles of 2018, a survey was created and distributed to members of the Society of Infectious Diseases Pharmacists (SIDP) asking members to vote on their top 10 general ID publications and 1 HIV publication. Of the 462 members surveyed, 213 (46%) and 108 (23%) voted for general ID pharmacotherapy-and HIV-related articles, respectively. The top article(s) for both categories are summarized. Conclusion: With the increased emphasis on antimicrobial stewardship initiatives and the growing problem of multidrug-resistant (MDR) organisms, the amount of ID literature centered on stewardship, appropriate treatment durations, and newly approved antimicrobial agents continues to expand, making it challenging for clinicians to stay informed on the most relevant publications. This review summarizes significant ID-related publications in 2018 with the goal of aiding clinicians in staying up to date on the most noteworthy publications in ID pharmacotherapy.
Introduction
The increasing number of infectious diseases (ID)-related publications makes it challenging for clinicians to keep up to date with new literature. The increased focus of the ID community on antimicrobial stewardship efforts as well as the growing threat of multidrug-resistant (MDR) organisms in recent years has contributed to the increased number of published ID articles. In 2018 alone, a PubMed search with the keywords "infectious diseases" and "HIV" identified 30 880 and 15 849 publications, respectively, highlighting the challenge of keeping informed on new literature. As the number of peer-reviewed publications on ID pharmacotherapy continues to grow, it is important for clinicians to stay current on practice-altering developments and changes to standards of care.
The Houston Infectious Diseases Network (HIDN) consists of ID clinicians from the Texas Medical Center and the greater Houston area, including ID physicians, pharmacists, microbiologists, and researchers from over 15 different institutions. This network meets regularly to collaborate on research, education, stewardship, and best practices and is involved in the mentorship of fellows, residents, and students. Each year since 2009, the HIDN has led efforts to compile and review the top 10 significant publications in ID pharmacotherapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] The purpose of this annual publication is to provide clinicians with an easily accessible summary of some of the most important developments in the field. Similar to previous years, at the end of 2018, HIDN members were asked to nominate articles thought to have most influenced ID pharmacotherapy practice in 2018, including those related to human immunodeficiency virus (HIV). All nominated articles must have been published between January 1, 2018, and December 31, 2018, in peerreviewed journals. Altogether, there were 26 nominations: 22 general ID articles and 4 HIV/AIDS articles.
In January 2019, members from the Society of Infectious Diseases Pharmacists (SIDP) were invited to participate in an electronic survey of nominated articles. Members were asked to select the top 10 articles that they believed contributed most to general ID pharmacotherapy and the 1 article most important to HIV/AIDS pharmacotherapy. Participants were given the option to nominate articles not included in the original survey, with each nomination counting as one vote. They were also allowed to opt out of voting in either category. Final ranking was determined by total survey response counts.
A total of 462 SIDP members in the United States responded to the survey. Of those who responded, 213 (46%) and 108 (23%) members voted for general ID pharmacotherapy-and HIV/AIDS-related articles, respectively. The 11 papers (10 general ID and 1 HIV/AIDS) with the highest rankings are summarized below. The articles are listed in alphabetical order by the lead author's last name. The final rankings of the top 20 ID and 4 HIV/AIDS articles are listed in Tables 1 and 2 , respectively. The 2018 Clinical and Laboratory Standards Institute (CLSI) designated a minimum inhibitory concentration (MIC) of 4 mg/L as the daptomycin susceptibility breakpoint for enterococcal infections. 34 However, neither preclinical pharmacodynamic (PD) data nor randomized controlled trials have investigated the appropriateness of this value. Given this knowledge gap, additional research is needed to determine the proper MIC breakpoint for serious enterococcal infections.
Avery et al conducted a retrospective PD analysis using data from 7 previously published observational studies to determine the optimal daptomycin-free drug area under the concentration-time curve to MIC ratio (fAUC/MIC) associated with improved 30-day survival rates in enterococcal bacteremia. Included in the study were pooled outcomes data for adult patients treated with daptomycin for enterococcal bacteremia from 7 observational studies. Patients were excluded if they received daptomycin for <72 hours, received active combination therapy (intravenous aminoglycosides, any b-lactam, linezolid, tigecycline, or vancomycin), received continuous renal replacement therapy, or attained bloodstream clearance prior to daptomycin initiation. The primary outcome assessed was 30-day survival, and the secondary outcome was microbiological response, defined as blood culture clearance on daptomycin prior to day 4 from index culture and absence of infection recurrence within 7 days of initial clearance.
A population pharmacokinetic (PK) model was used to estimate daptomycin clearance in each patient, which allowed the investigators to calculate the fAUC and fAUC/MIC ratio using daptomycin ETEST ® MIC results. A classification and regression tree analysis was performed to identify the fAUC/MIC thresholds most predictive of 30-day survival and microbiological response. After the PD threshold was determined, it was applied in Monte Carlo simulations (5000 female and 5000 male simulations) to determine the probability of target attainment (PTA) of various daptomycin dosing regimens (6, 8, 10 , and 12 mg/kg/d). The fAUC/MIC PTA was calculated for doubling MIC dilutions between 0.25 and 16 mg/L, and an a priori PTA >90% was defined as optimal.
Of the 460 patients identified, 114 remained after applying exclusion criteria. Overall, 58.8% of the patients survived through day 30. The median daptomycin MIC was 2 mg/L and did not differ between alive and deceased patients (P ¼ .607). The authors identified a fAUC/MIC threshold of >27.43 for improved 30-day survival in low-acuity patients (n ¼ 77; P ¼ .006), but were not able to determine a threshold for microbiological response. After controlling for catheter source and immunosuppression, an fAUC/MIC ratio of >27. 43 Limitations include the retrospective nature of the study, the lack of patient-specific PK data, and the inability to control for source control as a covariate. Nonetheless, this and other studies have demonstrated the need for a lowered susceptibility breakpoint in order to achieve optimal PD thresholds for serious enterococcal infections. CLSI has responded to these data by recently revising the breakpoints to the following: susceptible MIC 1 mg/L, susceptible dose-dependent MIC 2-4 mg/L, and resistant MIC >8 mg/L. Extended-spectrum b-lactamase (ESBL)-producing Gramnegative bacteria are a global public health concern as they confer resistance to penicillins and third-generation cephalosporins. 36, 37 Despite inhibition by tazobactam, carbapenems are considered the drug of choice for treating bloodstream infections (BSIs) caused by ESBL-producing Enterobacteriaceae due to limited retrospective studies and conflicting results with piperacillin-tazobactam treatment. [38] [39] [40] [41] [42] Given concerns for increasing carbapenem resistance, the MERINO trial tested whether a carbapenem-sparing regimen (piperacillin-tazobactam) was noninferior to meropenem for the definitive treatment of BSI caused by Escherichia coli or Klebsiella species with susceptibilities phenotypically compatible with ESBL production.
Harris et al conducted a noninferiority, open-label, randomized controlled trial including hospitalized adult patients from 26 sites in 9 countries between February 2014 and July 2017. Adult patients were eligible if they had at least 1 positive blood culture with Escherichia coli or Klebsiella spp. testing nonsusceptible to ceftriaxone or cefotaxime, yet remained susceptible to piperacillin-tazobactam and meropenem. Notable exclusion criteria included receipt of concomitant antibiotics with activity against Gram-negative bacilli and expected survival for <96 hours. Patients were randomly assigned in a 1:1 ratio (stratified by disease severity, source of infection, and infecting species) to receive either meropenem (1 g every 8 hours) or piperacillin-tazobactam (4.5 g every 6 hours) within 72 hours of index blood culture. All doses were infused over 30 minutes, and treatment was continued for 4 to 14 days as determined by the treating clinician. The primary efficacy outcome was all-cause mortality at 30 days after randomization, with notable secondary outcomes including microbiological relapse rates and serious adverse events.
Of the 378 patients included in the primary analysis, 187 received piperacillin-tazobactam and 191 received meropenem. Demographic characteristics were similar between groups, and the majority of BSIs were secondary to a urinary tract infection (61%) and caused by Escherichia coli (87%). Following an interim analysis, the trial was suspended after a primary outcome difference was observed approximating the prespecified stopping rule (P ¼ .004). The 30-day mortality rate was 12.3% in patients treated with piperacillin-tazobactam compared to 3.7% in those treated with meropenem (difference, 8.6%; 97.5% CI, À1 to 14.5%; P ¼ .90 for noninferiority). Clinical and microbiological resolution by day 4 occurred in 68.4% of the piperacillintazobactam group compared with 74.6% of the meropenem group (difference, À6.2%; 95% CI, À15.5% to 3.1%; P ¼ . 19 ). There were no significant differences observed in other secondary outcomes, including rates of microbiological relapse, secondary infection with another MDR organism, Clostridioides difficile infection, and nonfatal serious adverse events. ESBL genes were confirmed in 85.3% of isolates.
Limitations to this study include a lower than expected overall mortality rate (7.9%), high treatment crossover between the start of empiric treatment and study drug assignment, and an unblinded study design. However, this is the first randomized controlled trial investigating the optimal treatment for ESBLproducing Gram-negative bacteremia and this high-quality evidence does not support piperacillin-tazobactam for definitive treatment of BSIs involving ceftriaxone-resistant Escherichia coli or Klebsiella species.
Huttner et al. Effect of 5-Day Nitrofurantoin vs SingleDose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women 17
Treatment options for urinary tract infections (UTIs) are limited due to increasing antimicrobial resistance. In 2010, nitrofurantoin and fosfomycin were added as first-line agents for the treatment of uncomplicated UTIs in clinical practice guidelines. 43 Although nitrofurantoin has shown comparable clinical efficacy to other agents, the data for fosfomycin are limited. 43, 44 Given fosfomycin is administered as a single-dose regimen, there may be concern for decreased activity and efficacy or urinary concentration variability in patients. 45, 46 Huttner et al conducted a multicenter, open-label, analystblinded, randomized clinical trial from 2013 to 2017 comparing the clinical efficacy of 5-day nitrofurantoin versus single-dose fosfomycin for uncomplicated UTI. Adult women aged !18 years old with at least 1 symptom of acute lower UTI (dysuria, frequency, urgency, or suprapubic tenderness) and a urine dipstick positive for nitrites or leukocyte esterase were included. Exclusion criteria included pregnancy and lactation, suspected upper UTI, prior antibiotic use or symptoms of UTI in the prior 4 weeks, immunosuppressed state, and renal insufficiency (creatinine clearance <30 mL/min). Patients were randomized in a 1:1 ratio to either oral nitrofurantoin macrocrystalline (100 mg 3 times daily for 5 days) or fosfomycin tromethamine (single 3 g oral dose). The primary outcome, clinical response at day 28 (+7) after therapy completion, was stratified into 3 categories: clinical resolution (complete resolution of UTI signs and symptoms), failure (discontinuation, alteration, or addition of antibiotic therapy), or indeterminate (symptom persistence in the absence of documented infection). Notable secondary outcomes included bacteriologic response (eradication with no recurrence or failure with presence of bacteruria) and incidence of adverse effects.
A total of 513 patients were randomized (255 nitrofurantoin, 258 fosfomycin); 28 patients (11 nitrofurantoin, 17 fosfomycin) had missing data for the primary outcome measure. There were no differences in baseline demographics between the 2 treatment groups. Of the 487 patients with baseline urine cultures, 77% were positive; predominant organisms included Escherichia coli (61%), Klebsiella spp. (7%), Enterococcus spp. (7%), and Proteus spp. (5%). Clinical resolution was observed in 70% of patients receiving nitrofurantoin versus 58% of patients receiving fosfomycin (difference, 12%; 95% CI, 4%-21%; P ¼ .004). Among patients with positive baseline cultures, 74% and 63% had no bacteriologic recurrence on day 28 in the nitrofurantoin and fosfomycin groups, respectively (difference, 11%; 95% CI, 1%-20%; P ¼ .04). Incidence of adverse effects was uncommon and similar between both groups.
Limitations to this study included the open-label design that may have introduced measurement bias given the subjective primary outcome, potential heterogeneity in microbiologic methods given noncentralized laboratory analyses, and site differences including local resistance prevalence given over-the-counter sales of nitrofuran derivatives in one site. Despite these limitations, nitrofurantoin, compared to oral, single-dose fosfomycin, was associated with significantly greater clinical and microbiological resolution at 28 days after therapy in women with uncomplicated UTI.
Iversen et al. Partial Oral Versus Intravenous Antibiotic Treatment of Endocarditis 12
Left-sided infective endocarditis is routinely treated for up to 6 weeks with intravenous antibiotics. 47 Given the long duration of intravenous antibiotics, patients may be at an increased risk for complications whether they are treated in a hospital or given outpatient parenteral treatment. Although the clinical evidence for safety and efficacy of oral antibiotic therapy is limited, it may alleviate some of the challenges of intravenous therapy. [48] [49] [50] [51] Iversen et al conducted a multicenter, randomized, unblinded, noninferiority trial in Denmark to evaluate the safety and efficacy of switching clinically stable patients from intravenous to oral antibiotics for the treatment of endocarditis. Patients who were receiving intravenous antibiotics for the treatment of left-sided endocarditis (native or prosthetic valve) and had blood cultures positive for Streptococci, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci were included if they were !18 years, in stable condition, and fulfilled the modified Duke criteria. 46 Patients had to receive at least 10 days of intravenous antibiotics before randomization and have at least 10 days of scheduled antibiotics remaining at the time of randomization. Patients were randomized in a 1:1 ratio to continue intravenous antibiotic therapy or shift to orally administered antibiotic therapy. Oral regimens included 2 moderately or highly bioavailable antibiotics from different drug classes with different mechanisms of action. Plasma levels of rifampicin, moxifloxacin, linezolid, fusidic acid, amoxicillin, dicloxacillin, and clindamycin were obtained to ensure appropriate dosing. The primary outcome was a composite of all-cause mortality, clinically evident embolic events, unplanned cardiac surgery, or relapse of bacteremia with the primary pathogen from trial onset through 6 months after completion of therapy. Patients were followed up at 1 week and 1, 3, and 6 months after completion of antibiotic treatment.
Overall, 400 patients were included (199 continued intravenous treatment, 201 shifted to oral treatment) and baseline characteristics were similar between the 2 groups. Oral therapy consisted of 2 to 4 pathogen-specific combination regimens, predominantly featuring one of linezolid, amoxicillin, or dicloxacillin paired with fusidic acid, rifampicin, or moxifloxacin. The most frequently identified organism was Streptococci. Median time to randomization was 17 days in both groups, followed by median treatment durations of 19 days (interquartile range [IQR]: 14-25) and 17 days (IQR: [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] for the intravenous and oral groups, respectively. Median length of stay (LOS) after randomization was 19 days (IQR: 14-25) and 3 days (IQR: 1-10) for the intravenous and oral groups, respectively (P < .001). The primary outcome was observed in 12.1% of patients treated with intravenous therapy and in 9.0% of those receiving oral therapy, which met noninferiority (difference, 3.1%; 95% CI, À3.4% to 9.6%; P ¼ . 40 and OR, 0.72; 95% CI, 0.37-1.36). No antibiotic regimens were changed in response to PK findings. There were no significant differences in adverse effects between the groups.
Study limitations included enrollment of only patients with left-sided endocarditis, only 5 intravenous drug users, lack of standardized oral regimens, and there being no patients with methicillin-resistant S aureus (MRSA) or other antibioticresistant phenotypes, which may limit generalizability to those populations. Although the optimal oral regimens have yet to be determined, patients in stable condition with infective endocarditis meeting select criteria may benefit from a shift from intravenous to orally administered antibiotic treatment. Overall, the cohorts were similar (45 episodes in cohort 1, 37 episodes in cohort 2) and were predominantly acute myeloid leukemia (57.8% vs 67.6%) patients undergoing induction chemotherapy (35.6% vs 27%), respectively. There were more patients undergoing allogeneic SCT (31.1% vs 8.2%; P ¼ .01) and a longer duration of neutropenia (20 Study limitations include no randomization or blinding, small sample size, and an imbalance in allogenic SCT patients and antibacterial prophylaxis used. In summary, this study adds additional information suggesting short course (SC; 5 days) empirical antibiotic therapy, even for those without fever resolution, may be an approach in appropriately selected patients with FN without a clinical/radiologic source of infection, positive cultures, or septic shock.
Parente et al. The Clinical Utility of Methicillin-Resistant
Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications 13 The Infectious Diseases Society of America/American Thoracic Society guidelines on pneumonia recommend empiric MRSA coverage in at-risk patients despite low prevalence of MRSA pneumonia. 57, 58 Although timely antimicrobial therapy is essential for improving patient outcomes, clinicians are challenged with appropriate initiation and de-escalation of anti-MRSA therapy. This quandary is often compounded by inadequate or absent respiratory cultures. Recent literature on MRSA, a common nares colonizer, has highlighted that nasal screening may be a useful tool for clinicians and antimicrobial stewardship programs (ASPs) in assessing the need for empiric MRSA therapy.
Parente et al conducted a systematic review and metaanalysis of published literature and conference abstracts from inception through March 2017 to evaluate the diagnostic value of MRSA nasal screening in ruling out potential MRSA pneumonia. Studies were excluded if they were non-English, only utilized MRSA surveillance culture studies from other body sites, or were zero-event studies (eg, absence of MRSA pneumonia diagnosed). Outcomes evaluated included the performance characteristics of sensitivity, specificity, diagnostic ORs, likelihood ratios, positive predictive values (PPVs), and negative predictive values (NPVs).
Twenty-two studies with 5163 patients were included. Majority were conducted at academic medical centers and were retrospective. Of the 22 studies, only 11 evaluated pneumonia classification, including community-acquired pneumonia (CAP), health-care-associated pneumonia (HCAP), and ventilator-associated pneumonia (VAP), with the following evaluation distribution: all 3 categories (27.3%), only VAP (45.5%), CAP and HCAP (18.2%), and "nosocomial" pneumonia (9.1%). The majority of studies confirmed the diagnosis of pneumonia with radiographic evidence, respiratory cultures, and/or other clinical criteria. The most common MRSA nares surveillance method was polymerase chain reaction (PCR; 50%), followed by culture-based identification (18.2%) or a combination of both (4.5%), while the remainder did not specify detection method (27.3%). In 63.6% of the studies, MRSA nares surveillance culture was obtained at admission to the hospital or the ICU or within 24 hours of admission.
The pooled overall prevalence of MRSA pneumonia was 10% (95% CI, 8%-13%; P < .001). The MRSA nares screening capability for MRSA pneumonia across all pneumonia types was as follows: sensitivity 70.9% (95% CI, 58.8%-80.6%), specificity 90.3% (95% CI, 86.1%-93.3%), PPV 44.8%, and NPV 96.5%. CAP/HCAP showed the highest sensitivity, specificity, PPV, and NPV of the MRSA nares screen at 85% (95% CI, 59.7%-95.6%), 92.1% (95% CI, 81.5%-96.9%), 56.8%, and 98.1%, respectively. For VAP, the sensitivity and PPV were lower at 40.3% (95% CI, 17.4%-68.4%) and 35.7%, respectively. However, the specificity and NPV for VAP remained high at 93.7% (95% CI, 77.1%-98.4%) and 94.8%, respectively. Meta-regression was used to check for heterogeneity and revealed several covariates including study design (prospective vs retrospective; P ¼ .01), testing method (PCR vs other methods; P ¼ .01), timing of testing (at admission vs other times; P ¼ .02), and pneumonia type (VAP vs other types; P ¼ .01).
Limitations include inclusion of mostly retrospective studies, variation in diagnosis and classification of pneumonia, and lack of consistency in timing of nasal swab collection in relation to respiratory culture. Despite these limitations, the meta-analysis suggests that while a positive MRSA nares test is not diagnostic of MRSA pneumonia, a negative result rapidly and effectively rules it out. The MRSA nares screening is a rapid, inexpensive way for ASPs to de-escalate anti-MRSA therapy in patients with pneumonia, particularly those not colonized with MRSA. Historically, treatment options for carbapenem-resistant Enterobacteriaceae (CRE) have been limited to combination therapy that often included agents such the polymyxin, tigecycline, and aminogylcosides. [59] [60] [61] [62] These agents are associated with limited efficacy, significant toxicity, and dosing uncertainties. In 2015, the Food and Drug Administration approved ceftazidimeavibactam (CZA), a third-generation cephalosporin combined with a novel non-b-lactam b-lactamase inhibitor, that has activity against Ambler class A and class D serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). Since then, there have been limited studies comparing outcomes of patients treated with CZA versus colistin for CRE infections. 59, 63 van Duin et al conducted a prospective, observational study from the Consortium on Resistance Against Carbapenems in Klebsiella and Other Enterobacteriaceae (CRACKLE) 64 study comparing the outcomes in patients initially treated with CZA versus colistin for CRE infections. Patients who started CZA or colistin treatment for a documented CRE infection from December 2011 to May 2016 were included. Patients were excluded if they were started on CZA and colistin within a 24-hour window or if their culture episode did not meet criteria for infection. Novel statistical methods, including desirability of outcome ranking (DOOR) and partial credit analyses, utilizing ordinal outcomes, were applied to allow for a more complete evaluation of risks and benefits.
A total of 137 patients within the CRACKLE study met inclusion criteria, including 38 (28%) receiving CZA and 99 (72%) receiving colistin. The majority of patients presented with CRE BSI (n ¼ 63; 46%), followed by CRE respiratory tract infections (n ¼ 30; 22%). K pneumoniae was the most common causative organism (n ¼ 133; 97%), of which 28 and 24 isolates were positive for bla KPC-2 and bla KPC-3 , respectively. Combination therapy was common; however, fewer patients in the CZA group received additional CRE-active antibiotics (63% vs 94%; P < .001). Carbapenems and/or tigecycline were the most common combination agents for both groups. After inverse probability of treatment weighting (IPTW) adjustment, 30-day all-cause mortality was 9% in the CZA group and 32% in the colistin group (difference, 23%; 95% CI, 9%-35%; P ¼ .001). DOOR analyses revealed that the IPTW-adjusted probability of a better outcome on CZA versus colistin was 64% (95% CI, 57%-71%). Safety in patients without renal failure at treatment initiation (n ¼ 72) was measured with the following IPTW-adjusted ordinal outcomes: hospital death, no death with incident renal failure, and no death without renal failure. CZA showed a more favorable safety profile (9%, 5%, and 86%, respectively) compared to colistin (25%, 13%, and 62%) and a DOOR analysis indicated a 62% (95% CI, 52%-72%) probability of a better safety outcome with CZA. CZA was also advantageous over colistin in the IPTW-adjusted ordinal benefit-risk outcomes with a larger probability of favorable outcomes such as alive in the hospital/discharged not to home without incident renal failure (65% vs 56%) or discharged home (20% vs 8%).
The study was limited by its small sample size, observational study design, and potential unmeasurable confounding from lack of randomization. Nevertheless, the author's findings demonstrate improved outcomes with CZA over colistin for the initial treatment of CRE. Questions regarding efficacy of CZA monotherapy compared to combination therapy remain unclear. 19 Treatment of Staphylococcus aureus bacteremia (SAB) has traditionally been limited to intravenous therapy owing to significant mortality, high incidence of metastatic foci, and high rates of relapse. 65, 66 However, a limited, but growing body of evidence looking at oral therapy for SAB is available. [67] [68] [69] Willekens et al conducted a prospective, observational, nonblinded, propensity-matched cohort study of SAB treatment with standard parenteral therapy (SPT) versus early switch to oral linezolid therapy (ELT) in Spain. Patients were included in the SPT group if the entire course of antibiotic therapy was intravenous and in the ELT group if transitioned to oral linezolid on days 3 to 9 after active SAB therapy initiated and continued until therapy completion. Patients were excluded for death within 7 days of index culture, complicated SAB, osteoarticular infection, oral SAB treatment other than linezolid, and incomplete follow-up. The primary outcome was 90-day relapse (new SAB or other microbiologically confirmed S aureus infection within 90 days of therapy completion).
Willekens et al. Early Oral Switch to Linezolid for
The entire cohort included 107 SPT and 45 ELT patients from January 2013 to January 2017. The propensity-matched cohort was derived in a 2:1 ratio of SPT to ELT (SPT, n ¼ 90; ELT, n ¼ 45) based on malignancy, cirrhosis, renal disease, predisposing factors for endovascular/endocarditis infection, acquisition location, septic shock, ICU stay duration, ID consultation, time to treatment, gender, methicillin resistance, Charlson comorbidity score, immunosuppression, neutropenia, and bacteremia source. No statistically significant differences in baseline characteristics were present in the propensitymatched cohort groups aside from more chronic renal disease in subjects in the SPT group (22.2% vs 4.4%; P ¼ .02). The majority of the SPT and ELT groups in the propensity-matched cohort had catheter-related infections (46.7% vs 55.6%) and few required ICU care (17.8% vs 8.9%; P ¼ .27). There was no difference in 90-relapse between SPT and ELT groups in the whole cohort (3.7% vs 2.2%; P ¼ 1.00) or the propensitymatched cohort (4.4% vs 2.2%; P ¼ .87), respectively. Mortality at 30 days was higher for the SPT group in the whole cohort (15.9% vs 2.2%; P ¼ .04) and a trend was present in the propensity-matched cohort (13.3% vs 2.2%; P ¼ .08). Hospital LOS was longer for the SPT group in the whole (19 days vs 8 days; P < .01) and propensity-matched cohorts (19 days vs 8 days; P < .01). On univariate and multivariate analysis, 90-day relapse was not associated with ELT. Multivariate analysis identified neutropenia (OR: 69.9; 95% CI, 1.4-3589.3; P ¼ .04), prosthetic valve (OR: 445.4; 95% CI, 5.4-36753.3; P < .01), time to appropriate therapy (OR: 5.8; 95% CI, 1.7-20.3; P < 0.01), and time to ID consult (OR: 1.6; 95% CI, 1-2.5; P ¼ .05) as associated with 90-day relapse.
Study limitations include nonrandomized and observational approach, small sample size, relatively low severity of illness, and baseline characteristic differences despite propensity matching. Although this study adds to a growing body of literature demonstrating potential for partial oral SAB therapy in select patients, routine adoption of this approach is not recommended pending results from the ongoing, randomized SABATO trial. Treatment of CRE infections is complicated by limited and second-line treatment options associated with significant morbidity and mortality. 71, 72 The addition of vaborbactam, a novel, boron-based, beta-lactamase inhibitor, to meropenem has yielded a new therapeutic agent with activity against serine carbapenemases, particularly KPC. 73 The TANGO II trial sought to determine the efficacy and safety of meropenemvaborbactam (MVB) monotherapy compared to best available therapy (BAT) for CRE.
Wunderink et al conducted a phase III, prospective, multicenter, multinational, open-label, randomized controlled trial enrolling patients from 27 hospital sites in 8 countries between November 2014 and June 2017. Included patients were !18 years old with bacteremia, hospital-acquired/ventilatorassociated bacterial pneumonia (HABP/VABP), complicated intra-abdominal infection (cIAI), or complicated urinary tract infection/acute pyelonephritis (cUTI/AP) with confirmed or suspected CRE infection requiring at least 7 days of intravenous treatment. Exclusion criteria included allergy to beta-lactams, CRE-producing metallo-and oxacillinase beta-lactamases, Acute Physiology and Chronic Health Evaluation score >30, or presence of life-threatening disease. Patients were randomized 2:1 to MVB or BAT, which was monotherapy or combination therapy of polymyxins, carbapenems, aminoglycosides, or tigecycline, or monotherapy with CZA. The primary outcome was clinical cure, defined as complete resolution of signs/symptoms of the index infection requiring no further antimicrobial therapy, at end of treatment (EOT), and test of cure (TOC). Other outcomes included day-28 all-cause mortality, microbiological cure, and adverse events.
A total of 77 patients were enrolled, with 52 and 25 patients in the MVB and BAT arms, respectively. Within the modified intent-to-treat (MITT) population of patients receiving at least 1 dose of study drug, infections by type included bacteremia (36%, 27 of 75), cUTI/AP (45.3%, 34 of 75), HABP/VABP (9.3%, 7 of 75), and cIAI (9.3%, 7 of 75). Klebsiella pneumoniae was the most common organism of both the MITT (58.7%, 44/75) Shorter antibiotic courses are becoming clinically accepted and widely adopted for many infections, including pulmonary, skin, and abdominal infections. 57, [74] [75] [76] Although many Gramnegative infections are often treated for an arbitrarily selected 14 days, retrospective studies that sought to determine the optimal duration of therapy (DOT) for Gram-negative bacteremia have reported conflicting results and minimally impacted the current management of these infections. [77] [78] [79] [80] Randomized controlled trials (RCTs) are needed to elucidate the optimal duration of antibiotic therapy for Gram-negative bacteremia.
Yahav et al conducted a multicenter, open-label, RCT in Israel and Italy to determine the optimal DOT for uncomplicated aerobic Gram-negative bacteremia. Investigators randomized adults hospitalized between 2013 and 2017 to SC (7 days) or long-course (LC; 14 days) on day 7 of antimicrobial therapy if they were hemodynamically stable and afebrile for !48 hours. Patients with urinary tract, intra-abdominal, skin and soft tissue, central venous catheter, respiratory tract, or unknown source of bacteremia were included. Exclusion criteria were polymicrobial bacteremia, persistent bacteremia, uncontrolled foci of infection, HIV infection, neutropenia, or recent allogeneic hematopoietic stem cell transplantation. The primary outcome, measured 90 days from randomization, was a composite of all-cause mortality, clinical failure, and readmission or extended hospital stay beyond 14 days. Secondary outcomes included development of a new infection, development of resistance, time to return to baseline activity, and adverse events, including Clostridioides difficile infection.
Overall, 604 patients were randomized (SC, n ¼ 306; LC, n ¼ 296). There was no difference in patient demographics between the 2 treatment arms with a median age of 71 years (interquartile range [IQR], 62-81) and median Charlson comorbidity score of 2 (IQR, 1-4). Infections were hospital acquired in 29.1% of patients, and 8.4% had received a solid organ transplantation (SOT). The source of bacteremia was the urinary tract in 68% of patients, followed by the abdomen (11.7%), primary bacteremia (8.4%), central venous catheter (6.2%), the respiratory tract (3.9%), and skin and soft tissue (1.5%). The causative pathogen was Escherichia coli in 62.9% of patients, followed by Klebsiella spp. (13.2%), other Enterobacteriaceae (13.7%), and Pseudomonas species (7.9%). MDR bacteria were isolated from 18.0% of patients, 96.3% of which were deemed ESBL-producing based on phenotypic evaluation. Of note, 64% and 81.2% of patients in the SC and LC arms, respectively, received oral antibiotics as part of their treatment with the most common agents across both arms being fluoroquinolones (*70%) and beta-lactams (*20%). The primary outcome in the intention-to-treat population occurred in 45.8% and 48.3% of patients in the SC and LC arms, respectively (risk difference, À2.6%, 95% CI, À10.5% to 5.3%, P ¼ .527). No significant between-group differences were observed in any of the individual primary outcome components. Furthermore, no significant differences were observed in most of the secondary outcomes; however, the time to return to baseline activity was significantly shorter in the SC arm (median 2 weeks [IQR, 0-8.3 weeks] vs 3 [1-12 weeks]; P ¼ .01).
Limitations of this trial include the small number of nonlactose-fermenting Gram-negative infections, a minimal SOT population with exclusion of other immunocompromised patients, and inadequate power to detect differences in all secondary outcomes. Despite these limitations, this large RCT demonstrates the safety and efficacy of SC antibiotic therapy for Gram-negative bacteremia in patients who have clinically improved by day 7 of treatment. Llibre et al conducted 2 phase III, open-label, parallelgroup, multicenter, randomized, noninferiority trials spanning 12 countries. Patients enrolled were !18 years old, on their first or second antiretroviral therapy (ART) regimen of 2 NRTIs plus NNRTI, INSTI, or PI, and virologically suppressed, defined as viral load <50 copies/mL, for at least 6 months at screening. Patients were randomized 1:1 to dolutegravir 50 mg daily plus rilpivirine 25 mg daily or CAR for 52 weeks. The primary efficacy end point was proportion of patients with viral load <50 copies/mL at week 48. Secondary end points at weeks 24 and 48 included snapshot efficacy and CD4 T-cell counts. Adverse events over 48 weeks, genotypic and phenotypic resistance, and incidence of drug discontinuation were also evaluated.
A total of 1028 patients were enrolled (516 in the dolutegravirÀrilpivirine arm and 512 continued CAR) from April through October 2015. The intent-to-treat population included 513 and 511 patients in each group, respectively. Baseline characteristics were similar between the 2 groups across both studies. Baseline ART regimens containing NNRTIs were most common (54% both groups). Pooled analysis of the primary end point, viral load <50 copies/mL at 48 weeks, demonstrated virological success in 95% of patients in both groups (adjusted treatment difference, À0.2%; 95% CI, À3.0 to 2.5). In the dolutegravirÀrilpivirine group, 3 patients experienced virological failure; viral resistance testing on one patient demonstrated no integrase or rilpivirine reduced susceptibility. An increase in median CD4 T-cell count from baseline to 48 weeks was reported in both groups (28.0 cells/mL, IQR: À55.0 to 112.5 in dolutegravir-rilpivirine vs 22.0 cells/mL, IQR: À46.0 to 108.0 in CAR). Adverse events were seen in 77% of dolutegravir-rilpivirine group versus 71% of CAR subjects, with psychiatric disorders (12% and 6%), nasopharyngitis (10% for both), and headache (8% and 5%) most commonly reported, respectively. Drug-related adverse events were reported more frequently in the dolutegravir-rilpivirine group (19%) versus CAR (2%), with the difference being driven by neuropsychiatric and central nervous system-related events. Similarly, adverse events leading to withdrawal from the study were more frequent in the dolutegravir-rilpivirine group (3% vs 1%), as were drug-related neuropsychiatric adverse events (5% vs <1%). No difference in lipid profile was detected.
Study limitations include open-label design and study completion in higher income countries. SWORD-1 and SWORD-2 demonstrated noninferiority of dolutegravir-rilpivirine compared to currently recommended antiretroviral treatment regimens in maintaining virological suppression over 48 weeks. Dolutegravir-rilpivirine provides a 2-drug regimen ART option for patients with sustained virological suppression on current antiretroviral therapy.
Conclusion
The number of significant ID pharmacotherapy-related publications is growing and clinicians are challenged with the difficult task of keeping abreast with the most recent and clinically impactful data. This review attempts to alleviate some of this burden by identifying and summarizing key articles published in 2018. This year's selections included articles on antimicrobial optimization and new antibacterial agents, highlighting the efforts of the ID community on antimicrobial stewardship and treatment of MDR infections.
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